Some studies have reported that the accuracy of MRI for neoadjuvant efficacy evaluation of breast cancer varies between different subtypes of breast cancer, and MRI is more suitable for evaluating the neoadjuvant therapy efficacy in human epidermal receptor-2 (HER2)-positive breast cancer and triple-negative breast cancer (TNBC) subtypes compared to luminal subtype [76]. Here, ERBB2 is linked to triple-negative breast carcinoma.